points were similar: median PFS (2.3 v 2.3 months, hazard ratio: 1.004 [0.841-1.199]), response rate (4.4% v 5.5%), stable disease (36.0% v 39.6%), median overall survival (6.7 v 7.2 months, hazard ratio: 0.973 [0.805-1.176]). Clinical benefit was a composite endpoint based on PS, weight, PPI, analgesic consumption, dyspnoea and cough; the primary endpoint of clinical benefit analysis was the rate of clinical benefit responders, defined as those patients who demonstrated improvement in at least one of these parameters, without deterioration in any other parameter, and confirmed once at least three weeks later. No significant difference was observed in the rate of clinical benefit between the vinflunine arm (31 responders, 13.1%, 95% CI 9.1-18.0) and the docetaxel arm (39 responders, 15.5%, 95% CI 11.3-20.6: c 2 , p=0.4389). Conclusion: Vinflunine 320 mg/m 2 every 3 weeks was found to be similar in terms of efficacy to docetaxel 75 mg/m 2 every 3 weeks in patients previously treated with a platinum-containing regimen for advanced NSCLC patients. Clinical benefit was also comparable for the two study treatments. Low, manageable but different toxicity profiles were observed in either arm allowing a good median relative dose intensity > 98%. Therefore, vinflunine offers a new and useful alternative for patients suffering from advanced NSCLC in second line setting.
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Cytotoxic Chemotherapy I, Mon Platinum-based chemotherapy doublets represent the standard first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), although toxicity is common. Several randomized trials trying to assess whether non-platinum combinations were as effective as platinum-based ones yielded conflicting results. Moreover, another not completely solved question is whether triplet regimens could be more effective than chemotherapy doublets. This 2 x 2 factorial trial aimed at answering both questions: (1) the role of replacing cisplatin (P) with vinorelbine (N), (2) the role of adding a third agent, ifosfamide (I), in a chemotherapy doublet with gemcitabine (G). Primary endpoint was overall survival (OS). Secondary endpoints were response rate (RR), progression-free survival (PFS) and toxicity. ; p = 0.705) for I-triplets vs I-non containing doublets, respectively. Grade 3-4 anaemia, leucopenia and thrombocytopenia were significantly more frequent in P-containing regimens; only grade 3-4 leucopenia was more common in I-triplets. Concerning non-haematological toxicity, only grade 3-4 nausea-vomiting was significantly increased in P-containing regimens; no other statistically significant difference in toxicity was observed. Conclusions: Results of this unplanned preliminary analysis indicate that replacing P with N or the addiction of I to a chemotherapy doublet regimen did not improve OS in the treatment of stage IIIB-IV NSCLC patients. However, P-containing regimens showed a statistically significant advantage in RR over P-free chemotherapy.
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